Cost-effectiveness of caspofungin versus liposomal amphotericin B in the treatment of systemic fungal infections: a systematic review of economic analyses

References

• Azie N, Neofytos D, Pfaller M, et al. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73(4):293–300.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Inf. 2012;18:53–67.
   PubMed Web of Science ®Google Scholar
• Ashley DE, Drew R, Johnson M, et al. Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options. Pharmacotherapy. 2012;32(10):890–901.
   PubMed Web of Science ®Google Scholar
• des Champs-Bro B, Leroy-Cotteau A, Mazingue F, et al. Invasive fungal infections: epidemiology and analysis of antifungal prescriptions in onco-haematology. J Clin Pharm Ther. 2011;36(2):152–160.
   PubMed Web of Science ®Google Scholar
• Dignani MC. Epidemiology of invasive fungal diseases on the basis of autopsy reports. F1000Prime Reports. 2014;6(81).
   PubMedGoogle Scholar
• Ha YE, Peck KR, Joo E-J, et al. Impact of first-line antifungal agents on the outcomes and costs of candidemia. Antimicrob Agents Chemother. 2012;56(7):3950–3956.
   PubMed Web of Science ®Google Scholar
• Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes among intravenous antifungal therapies for patients with invasive aspergillosis in the United States. Mycoses. 2011;54(5):e301–e312.
   Google Scholar
• Mistro S, Maciel IM, De Menezes RG, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54(12):1774–1777.
   PubMed Web of Science ®Google Scholar
• Álvarez-Lerma F, Rodriguez M, Soriano MC, et al. Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy. Rev Esp Quimioter. 2013;26(4):360–368.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Cancidas NDA 21-227 approval letter. 2001 Jan 26 [cited 2015 Apr 22]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21227_Cancidas.cfm
   Google Scholar
• Ascioglu S, Chan KA. Utilization and comparative effectiveness of caspofungin and voriconazole early after market approval in the U.S. PloS One. 2014;9(1):e83658.
   PubMed Web of Science ®Google Scholar
• Wade RL, Chaudhari P, Natoli JL, et al. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Diagn Microbiol Infect Dis. 2013;76(3):361–367.
   PubMed Web of Science ®Google Scholar
• Wang J-L, Chang C-H, Young-Xu Y, et al. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2010;54(6):2409–2419.
   PubMed Web of Science ®Google Scholar
• Zhang J, Gong Y, Wang K, et al. Caspofungin versus liposomal amphotericin B for treatment of invasive fungal infections or febrile neutropenia. Chin Med J. 2014;127(4):753–757.
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346:f1049.
   PubMed Web of Science ®Google Scholar
• Inflation, GDP deflator (annual%). 2014 [cited 2015 Jul 27]. Available from: http://data.worldbank.org/indicator/NY.GDP.DEFL.KD.ZG
   Google Scholar
• Wingard JR, Leather HL, Wood CA, et al. Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm. 2007;64(6):637–643.
   PubMed Web of Science ®Google Scholar
• Kaskel P, Tuschy S, Wagner A, et al. Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol. 2008;87(4):311–319.
   PubMed Web of Science ®Google Scholar
• Ament AJHA, Hübben MWA, Verweij PE, et al. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach. J Antimicrob Chemother. 2007;60(2):385–393.
   PubMed Web of Science ®Google Scholar
• Fujii RK, Manfrin DF, Lanzara GDA, et al. Cost-effectiveness evaluation of amphotericin B, amphotericin B liposomal, caspofungin and voriconazol in treating aspergillosis under the Brazilian public health care system perspective. Value Health. 2013;16(3):A89–A.
   Google Scholar
• Al-Badriyeh D, Liew D, Stewart K, et al. Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia. J Antimicrob Chemother. 2009;63(6):1276–1285.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, Gant V, McKenzie C, et al. A cost-effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007;78(6):532–539.
   PubMed Web of Science ®Google Scholar
• Naik S, Lundberg J, Kumar R, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia in Sweden. Scand J Infect Dis. 2011;43(6–7):504–514.
   PubMed Web of Science ®Google Scholar
• Stam WB, Aversa F, Kumar RN, et al. Economic evaluation of caspofungin versus liposomal amphotericin B for empiric antifungal treatment in patients with neutropenic fever in Italy. Value Health. 2008;11(5):830–841.
   PubMed Web of Science ®Google Scholar
• Turner SJ, Senol E, Kara A, et al. Pharmacoeconomic evaluation of caspofungin versus liposomal amphotericin B in empirical treatment of invasive fungal infections in Turkey. Int J Antimicrob Agents. 2013;42(3):276–280.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Eng J Med. 2004;351(14):1391–1402 .
   PubMed Web of Science ®Google Scholar
• Contreras-Hernández I, Mould-Quevedo J, Zendejas-Villanueva JL, et al. Economic evaluation of antifungal agents in non-neutropenic patients with invasive candidiasis in Mexico. Pharmacoeconomics (Spanish Research Articles). 2011;8(1):16–28.
   Google Scholar
• Gamboa Garay OA, Fuentes Pachón JC, Cuervo Maldonado SI, et al. Cost-effectiveness analysis of antifungal treatment strategies in patients with persistent febrile neutropenia and broad spectrum antibiotic treatment. Value Health (Regional Issues). 2012;1(2):201–210.
   Google Scholar
• Dixon S, McKeen E, Tabberer M, et al. Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature. PharmacoEconomics. 2004;22(7):421–433.
   PubMed Web of Science ®Google Scholar
• Turner SJ, Chen SCA, Slavin MA, et al. Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients. Exp Rev Pharmacoecon Outcomes Res. 2013;13(2):227–235 .
   PubMed Web of Science ®Google Scholar
• Romá-Sánchez E, Poveda-Andrés JL, García-Pellicer J, et al. [Cost-effectiveness analysis of the empirical antifungal strategy in oncohaematological patients]. Farm Hosp. 2008;32(1):7–17. Spanish.
   PubMedGoogle Scholar
• Ellis M, Spence D, De Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis. 1998;27(6):1406–1412.
   PubMed Web of Science ®Google Scholar
• Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225–232.
   PubMed Web of Science ®Google Scholar
• Kassamali Z, Danziger LH, Glowacki RC, et al. How low can you go? Use of low- and standard-dose liposomal amphotericin B for treatment of invasive fungal infections. Int J Infect Dis. 2013;17(8):e615–e620.
   Google Scholar
• Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98(3):711–718.
   PubMed Web of Science ®Google Scholar